Nasopharyngeal carcinoma

Chan, Anthony T.C.; Teo, Peter M.L.; Johnson, Philip J.

doi:10.1093/annonc/mdf179

Cited by 284 publications

(225 citation statements)

References 37 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Over 50%-70% of NPC patients present with advanced disease (stages II b-IV) with lymph node invasion or metastasis at the time of diagnosis. The rate of distant metastasis in recurrent NPC patients is up to 37% (Chan et al, 2002;Hong et al, 2010;Isobe et al, 1998;Skinner et al, 1991;Spano et al, 2003). Because of the special location of NPC, radiotherapy Fig.…”

Section: Discussionmentioning

confidence: 99%

Metformin Induces G1 Cell Cycle Arrest and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma Cells

Zhao

Wen

Jia

et al. 2011

The Anatomical Record

View full text Add to dashboard Cite

It has been reported that metformin, a biguanide derivative widely used in type II diabetic patients, has antitumor activities in some cancers by activation of AMP-activated protein kinase (AMPK). But its role in nasopharyngeal carcinoma (NPC) is not known. Here, we reported for the first time that 1-50 mM of metformin in a dose-and time-dependent manner suppressed cell proliferation and colony formation in NPC cell line, C666-1. Further studies revealed that the protein level of cyclin D1 decreased and the percentage of the cells in G0/G1 phase increased by 5 mM metformin treatment. Metformin also induced the phosphorylation of AMPK (T172) in a time-dependent manner. Mammalian target of rapamycin complex 1 (mTORC1), which is negatively regulated by AMPK and plays a central role in cell growth and proliferation, was inhibited by metformin, as manifested by dephosphorylation of its downstream targets 40S ribosomal S6 kinase 1 (S6K1) (T389), the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (T37/46) and S6 (S235/236) in C666-1 cells. In a summary, metformin prevents proliferation of C666-1 cells by down-regulating cyclin D1 level and inducing G1 cell cycle arrest. AMPK-mediated inhibition of mTORC1 signaling may be involved in this process. Anat Rec, 294:1337Rec, 294: -1343Rec, 294: , 2011. V V C 2011 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Metformin Induces G1 Cell Cycle Arrest and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma Cells

Zhao

Wen

Jia

et al. 2011

The Anatomical Record

View full text Add to dashboard Cite

show abstract

“…The incidence in southern China is reported to be about 80 cases per 100,000, which brings great threat to the local people (Chan et al, 2002). Because the early clinical symptoms are not obvious, at least 60% of patients with NPC present with locally advanced disease, while about 5-8% present with distant metastases at diagnosis (Fong et al, 1996;Heng et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy with or without Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Meta-analysis of 1,096 Patients from 11 Randomized Controlled Trials

Liang

Zhu²,

Jiang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…EBV is associated with virtually all cases of undifferentiated nasopharyngeal carcinoma (NPC) and has been classified as a group I carcinogen (15)(16)(17)(18). In addition to its potential role in the pathogenesis of NPC, EBV also provides a possible target for immunotherapy of NPC, since a limited number of viral genes are expressed in the neoplastic cells, including EBNA1, LMP1 and LMP2 (16,17,19,20).…”

Section: Introductionmentioning

confidence: 99%